Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer
Status:
Recruiting
Trial end date:
2026-05-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of vandetanib and everolimus when
given together in treating patients with cancer that has spread to other places in the body.
Vandetanib and everolimus may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth.